Evidence method
Level · gp.fundamentals.capex_revenue_ratio
14.85% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
RKDA · Dec 31, 2021
Arcadia Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-22-005253General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-381.53% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
65.38% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
-28.44% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-523.98% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
57.36% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
22.73% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History19 statesSelf-history eligible
Dec 31, 20210/7 normalizedLevel 3Mar 31, 20220/7 normalizedLevel 3Jun 30, 20220/7 normalizedLevel 3Sep 30, 20220/8 normalizedLevel 3Dec 31, 20220/8 normalizedLevel 3Mar 31, 20230/8 normalizedLevel 3Jun 30, 20230/8 normalizedLevel 3Sep 30, 20236/8 normalizedLevel 3Dec 31, 20237/8 normalizedLevel 3Mar 31, 20247/8 normalizedLevel 3Jun 30, 20247/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 8.67%
- Current
- 14.85%
- Delta
- 6.18%
- Previous
- -347.98%
- Current
- -381.53%
- Delta
- -33.55%
- Previous
- 229.25%
- Current
- 65.38%
- Delta
- -163.87%
- Previous
- -366.71%
- Current
- -523.98%
- Delta
- -157.27%
- Previous
- 43.69%
- Current
- 57.36%
- Delta
- 13.67%
- Previous
- 16.84%
- Current
- 22.73%
- Delta
- 5.89%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · RKDA Fundamental State →Has State · Arcadia Biosciences, Inc. →Transitioned To · RKDA CAPEX_INTENSITY_INCREASED →Transitioned To · RKDA CASH_GENERATION_DECREASED →Transitioned To · RKDA INVENTORY_PRESSURE_DECREASED →Transitioned To · RKDA PROFITABILITY_DECREASED →Transitioned To · RKDA R_AND_D_INTENSITY_INCREASED →Transitioned To · RKDA SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.